These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 10430267)
1. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Karrison TG; Vogelzang NJ Cancer; 1999 Aug; 86(3):546-7. PubMed ID: 10430267 [No Abstract] [Full Text] [Related]
2. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Astoul P; Picat-Joossen D; Viallat JR; Boutin C Cancer; 1998 Nov; 83(10):2099-104. PubMed ID: 9827714 [TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 in malignant pleural mesothelioma (and adenocarcinoma of the lung). The use of intrapleural and continuous intravenous infusions: preliminary results. Thatcher N; Taylor P; Carroll KB; Loriaux EM; Palmer P; Franks CR Cancer Treat Rev; 1989 Jun; 16 Suppl A():161-2. PubMed ID: 2788503 [No Abstract] [Full Text] [Related]
4. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Castagneto B; Zai S; Mutti L; Lazzaro A; Ridolfi R; Piccolini E; Ardizzoni A; Fumagalli L; Valsuani G; Botta M Lung Cancer; 2001; 31(2-3):303-10. PubMed ID: 11165411 [TBL] [Abstract][Full Text] [Related]
5. Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response. Stam TC; Swaak AJ; Kruit WH; Stoter G; Eggermont AM Eur J Clin Invest; 2000 Apr; 30(4):336-43. PubMed ID: 10759883 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapy in malignant pleural mesothelioma. A review. Ong ST; Vogelzang NJ J Clin Oncol; 1996 Mar; 14(3):1007-17. PubMed ID: 8622005 [TBL] [Abstract][Full Text] [Related]
7. Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment. Opitz I; Lardinois D; Arni S; Hillinger S; Vogt P; Odermatt B; Rousson V; Weder W Eur J Cardiothorac Surg; 2007 May; 31(5):773-8. PubMed ID: 17350855 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of mesothelioma with interferon gamma and interleukin 2]. Boutin C; Viallat JR; Astoul P Rev Pneumol Clin; 1990; 46(5):211-5. PubMed ID: 2127468 [TBL] [Abstract][Full Text] [Related]
9. Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future? Munck C; Mordon SR; Scherpereel A; Porte H; Dhalluin X; Betrouni N Ann Thorac Surg; 2015 Jun; 99(6):2237-45. PubMed ID: 25912746 [TBL] [Abstract][Full Text] [Related]
10. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. Rusch VW; Niedzwiecki D; Tao Y; Menendez-Botet C; Dnistrian A; Kelsen D; Saltz L; Markman M J Clin Oncol; 1992 Jun; 10(6):1001-6. PubMed ID: 1588364 [TBL] [Abstract][Full Text] [Related]
11. Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity? Porta C; Rizzo V; Zimatore M; Sartore-Bianchi A; Danova M; Mutti L Lung Cancer; 2002 Nov; 38(2):159-62. PubMed ID: 12399127 [TBL] [Abstract][Full Text] [Related]
12. Foscan-mediated photodynamic therapy and operation for malignant pleural mesothelioma. Schouwink H; Baas P Ann Thorac Surg; 2004 Jul; 78(1):388; author reply 388-9. PubMed ID: 15223483 [No Abstract] [Full Text] [Related]
14. A review of chemotherapy trials for malignant mesothelioma. Ryan CW; Herndon J; Vogelzang NJ Chest; 1998 Jan; 113(1 Suppl):66S-73S. PubMed ID: 9438693 [TBL] [Abstract][Full Text] [Related]
15. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Goey SH; Eggermont AM; Punt CJ; Slingerland R; Gratama JW; Oosterom R; Oskam R; Bolhuis RL; Stoter G Br J Cancer; 1995 Nov; 72(5):1283-8. PubMed ID: 7577483 [TBL] [Abstract][Full Text] [Related]
16. A case of repetitive intrapleural cancer chemotherapy using INFUSE-A-PORT for malignant mesothelioma. Omasa M; Hirata T; Shoji T; Bando T; Hasegawa S; Inui K; Wada H Thorac Cardiovasc Surg; 2001 Aug; 49(4):233-5. PubMed ID: 11505321 [TBL] [Abstract][Full Text] [Related]
17. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand? Agarwal V; Lind MJ; Cawkwell L Cancer Treat Rev; 2011 Nov; 37(7):533-42. PubMed ID: 21183281 [TBL] [Abstract][Full Text] [Related]
18. Pemetrexed in malignant pleural mesothelioma. Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163 [TBL] [Abstract][Full Text] [Related]
19. A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy, and long-term subcutaneous IL-2 in stage II-III malignant pleural mesothelioma. Rusch VW Eur J Cardiothorac Surg; 2007 Mar; 31(3):534-5. PubMed ID: 17267238 [No Abstract] [Full Text] [Related]
20. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]